2 active shortage notices across 2 countries.
Last updated 2 Aug 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Italy | critical | 1 | 1 Jun 2020 | — | AIFA |
| Canada | high | 1 | 1 Dec 2020 | — | HC |
Yes. As of the latest regulator updates, Ibritumomab Tiuxetan has 2 active shortage notices across 2 countries (Italy, Canada). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Ibritumomab Tiuxetan shortages to manufacturing problems. The exact cause varies by country and product — each notice on this page links to the official source.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.